What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

View Full Paper

Ask AI

Bookmark

Prophylaxis with factor VIII lowers annualized treated bleed rates compared to other interventions.
Mean annualized treated bleed rates were lower with prophylaxis: 0.2 with emicizumab for under 12 years.
Cohorts from various regions included participants with and without FVIII inhibitors, observed for up to 52 weeks.
All treatment approaches showed similar adverse event rates, confirming they are generally well tolerated.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis reports that prophylaxis with factor VIII reduces annualized bleeds in severe hemophilia A, indicating geographic treatment disparities.

Cite This Study

Lemos et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236dec7 https://doi.org/10.1182/blood-2025-3062

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis reports that prophylaxis with factor VIII reduces annualized bleeds in severe hemophilia A, indicating geographic treatment disparities.

RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

Key Points

Discussion

Implication

Cite This Study

RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading